Abstract
Non-small cell lung cancer (NSCLC), which is at the time of diagnoses 75-80% locally advanced disease or generalized, it is a disease with a high incidence and mortality. In an effort to improve therapeutic outcomes are therefore denied much attention to targeted therapy based on predictive markers to new therapeutic modalities, such as immunotherapy.